> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** AI Drug Discovery **Published:** 2026-09-09 06:09 KST **Entry ID:** 94 **Tags:** #gse333657 #psneat1 #PSNEAT1 #lncRNA #long-noncoding-RNA #ribosome-biogenesis #nucleolus #rRNA-processing #rRNA-transcription #POLR1 #POLR2 #ribosomal-RNA --- ## 🔬 Today's Top Findings ### 1. [AI-DD & Refractory NSCLC] Effect of PSNEAT1 knockout on gene expression and ribosome biogenesis in NCI-H1299 cells (GSE333657, score 9/9, n=6, Homo sapiens, pdat 2026/09/07 = 2 days ago, raw CSV files, the FRESHEST NOVEL lncRNA-PSNEAT1 / ribosome-biogenesis / NCI-H1299-NSCLC bulk-RNA-seq atlas in the entire 2026-09-09 hits.jsonl with the ONLY FRESH SCORE-9 entry today and the FIRST NON-RECYCLED score-9 since the GSE326553 Oprm1-A118G breakthrough in id:89 (2026-09-04) broke the recycled-score-9 ceiling — a direct AI-DD + refractory-lung-cancer + lncRNA-target-nomination + ribosome-biogenesis-stress input for the BB AI-DD + longevity lane) ### 2. [Refractory Cancer & Tumor-Autonomous Cytokine Signaling] Molecular and cellular consequences of tumor-autonomous IL-6 signaling in intrahepatic cholangiocarcinoma (GSE320081, score 6/6, n=36, Homo sapiens, pdat 2026/08/20 = 20 days ago, raw files available, the LARGEST-N (n=36) NOVEL intrahepatic-cholangiocarcinoma / tumor-autonomous-IL-6 / cytokine-signaling scRNA-seq atlas in the entire 2026-09-09 hits.jsonl — a direct refractory-cancer + tumor-microenvironment + IL-6-JAK-STAT3-axis + CCA-rare-cancer input for the BB clinical + AI-DD lane) ### 3. [Longevity & Musculoskeletal Aging] Spatial transcriptomics reveals microenvironmental heterogeneity in osteoarthritic subchondral bone (GSE342703, score 6/6, n=4, Homo sapiens, pdat 2026/08/09 = 31 days ago, raw files available, the FRESHEST NOVEL osteoarthritis / subchondral-bone-microenvironment / spatial-transcriptomics atlas in the entire 2026-09-09 hits.jsonl — a direct longevity + musculoskeletal-aging + cartilage-bone-crosstalk + senescent-OA-subchondral-target input for the BB longevity lane) ## 📋 Synthesis The 2026-09-09 06:00 KST research-watcher scan encountered the documented §20 silent-failure pattern at the foreground-terminal 120s timeout: `bash run.sh scan` returned exit 124 after the GEO query fan-out, but the prior `output/latest/hits.jsonl` was already populated at 06:02 KST today (108 hits across 27 queries, mtime preserved) for synthesis. Today the score-9 ceiling is broken by ONE FRESH NOVEL entry (GSE333657 PSNEAT1/ribosome biogenesis NCI-H1299 NSCLC, score 9, pdat 2026/09/07 = 2 days ago) — the FIRST NON-RECYCLED score-9 since the GSE326553 Oprm1-A118G breakthrough in id:89 broke the recycled-score-9 ceiling on 2026-09-04. The standard recycled-score-9 accessions (GSE277080, GSE328275, GSE328422, GSE337336, GSE326553, GSE311507, GSE281462-GSE281465, GSE334010, GSE331133) all still appear, but GSE333657 is the fresh-NOVEL breakthrough. The actionable NOVEL signals today come from the score 6-9 band after pdat-filter (≤31 days upper) + prior-id:90-id:93-dedupe + mammalian-taxon-filter + BB-domain-keyword-filter (peptide / refractory-cancer / NSCLC / lung-cancer / ribosome-biogenesis / PSNEAT1 / lncRNA / cholangiocarcinoma / CCA / IL-6 / JAK-STAT3 / osteoarthritis / OA / subchondral-bone / longevity / musculoskeletal-aging / cartilage). (1) **Effect of PSNEAT1 knockout on gene expression and ribosome biogenesis in NCI-H1299 cells** (GSE333657, watcher score 9, n=6, Homo sapiens, bulk RNA-seq 'Expression profiling by high throughput sequencing', pdat 2026/09/07 = 2 days ago, raw CSV files, raw_file_availability 'yes', watcher query 'OpenFold weights' [likely query-routing artifact — actual subject is PSNEAT1/ribosome biogenesis], collected_at 2026-09-08T21:02:57Z). (2) **Molecular and cellular consequences of tumor-autonomous IL-6 signaling in intrahepatic cholangiocarcinoma** (GSE320081, watcher score 6, n=36, Homo sapiens, pdat 2026/08/20 = 20 days ago). (3) **Spatial transcriptomics reveals microenvironmental heterogeneity in osteoarthritic subchondral bone** (GSE342703, watcher score 6, n=4, Homo sapiens, pdat 2026/08/09 = 31 days ago). --- ## 🎯 Highlights ### 1. Signal 1 — AI-DD + Refractory NSCLC + LncRNA Target + Ribosome Biogenesis / Effect of PSNEAT1 knockout on gene expression and ribosome biogenesis in NCI-H1299 cells [PSNEAT1 ribosome-biogenesis NSCLC bulk-RNA-seq atlas]: GSE333657 (watcher score 9, n=6, Homo sapiens, bulk RNA-seq 'Expression profiling by high throughput sequencing', pdat 2026/09/07 = 2 days ago, raw CSV files, raw_file_availability 'yes', watcher query 'OpenFold weights' [likely query-routing artifact — actual subject is PSNEAT1/ribosome biogenesis], collected_at 2026-09-08T21:02:57Z) is the FRESHEST NOVEL lncRNA-PSNEAT1 / ribosome-biogenesis / NCI-H1299-NSCLC bulk-RNA-seq atlas in the entire 2026-09-09 hits.jsonl with the ONLY FRESH SCORE-9 entry today — the FIRST NON-RECYCLED score-9 since the GSE326553 Oprm1-A118G breakthrough in id:89 (2026-09-04) broke the recycled-score-9 ceiling. It is a direct AI-DD + refractory-lung-cancer + lncRNA-target-nomination + ribosome-biogenesis-stress input for the BB AI-DD + longevity lane, distinct from id:93 GSE286944 Vimentin-compressive-force mechanobiology single-cell by mechanism (lncRNA-knockout + ribosome-biogenesis vs intermediate-filament + mechanical-force), from id:92 GSE345607 CRISPR-immune-inspired-spatiotemporal-switch by modality (lncRNA-bulk-RNA-seq vs CRISPR-mixed-modality), and from id:91 GSE334010 CTHRC1+ fibroblast lung atlas by mechanism (lncRNA-knockout vs fibrogenic-fibroblast-hub). Lung cancer is the leading cause of cancer-related-mortality worldwide (~1.8M deaths/year, ~2.2M new-cases/year), with NSCLC comprising ~85% of cases and KRAS-mutant-NSCLC (~25% of NSCLC) and EGFR-mutant-NSCLC (~15% in Asian-populations) representing the major molecularly-defined subtypes; refractory-NSCLC (treatment-resistant, post-TKI-resistance, post-immunotherapy-resistance, post-chemotherapy-resistance) remains a major clinical-need with 5-year-survival ~25% overall and <10% in stage-IV-disease. NCI-H1299 is a KRAS-mutant (KRAS-G12C) NSCLC cell line widely used as a model of KRAS-driven-lung-cancer. LncRNAs (long-non-coding-RNAs, >200nt-non-protein-coding-transcripts) have emerged as major cancer-drivers and -targets: MALAT1 (metastasis-associated-lung-adenocarcinoma-transcript-1), NEAT1 (nuclear-enriched-abundant-transcript-1), HOTAIR, H19, ANRIL, XIST, and the PSNEAT1 family (a putative paraspeckle-related-NEAT1-paralog) regulate chromatin-architecture, transcription, splicing, mRNA-stability, translation, and ribosome-biogenesis. Ribosome-biogenesis (the synthesis and assembly of ribosomal subunits, involving rRNA-transcription-by-POLR1/2, rRNA-processing, rpL/rpS ribosomal-protein-synthesis, and 60S/40S-subunit-assembly in the nucleolus) is a fundamental cancer-hallmark (Hanahan-Weinberg-hallmark-of-cancer ‘deregulating-cellular-energetics’ and 'sustained-proliferative-signaling') and a major therapeutic-target-class: the ribosome-biogenesis-stress response activates p53 via MDM2-sequestration-by-ribosomal-proteins (rpL5/rpL11/rpL23 → MDM2-binding → p53-stabilization → cell-cycle-arrest + apoptosis), and CX-5461 (a POLR1-inhibitor from Senhwa-Biosciences, in Phase-I/II-clinical-trials for BRCA-deficient-and-hematologic-malignancies), CX-3543 (quarfloxin, a G-quadruplex-stabilizer that disrupts nucleolin-rDNA-interaction), BMH-21 (a POLR1-degrader), and several ribosomal-protein-inhibitors are in clinical-development as ribosome-biogenesis-targeting-anticancer-agents. ### 2. Four-axis score — peptide 0/5 (no peptide component; this is a lncRNA-target-and-ribosome-biogenesis dataset); AI-agent infrastructure 5/5 (lncRNA-knockout bulk-RNA-seq + ribosome-biogenesis readout is the canonical foundation-layer input for AI-DD target nomination AND for AI-agent design — enables foundation-model training on lncRNA-perturbation-responses + ribosome-stress-signatures + cancer-specific-vulnerabilities); longevity 3/5 (lung-cancer has direct longevity implications via cancer-mortality and ribosome-biogenesis-decline is a hallmark of aging [senescent-cells-show-decreased-ribosome-biogenesis, decreased-protein-synthesis, decreased-proteostasis]); cost 5/5 (n=6 bulk-RNA-seq is fast to ingest, modest QC burden, raw CSV enable immediate re-analysis with the standard DESeq2/edgeR-limma-voom pipeline + GSEA/pathway-enrichment + ribosome-biogenesis-gene-set-scoring). The signal is actionable from the BB multiomics + AI-DD service stack as a PSNEAT1/lncRNA-target-nomination + ribosome-biogenesis-stress + refractory-NSCLC brief. ### 3. Why it matters for BB + action — Ingest GSE333657 raw CSV files via the standard bulk-RNA-seq analysis pipeline (FastQC + STAR/HISAT2 + featureCounts/HTSeq + DESeq2/edgeR-limma-voom with multiple-testing-correction via Benjamini-Hochberg at FDR<0.05), identify the PSNEAT1-knockout-vs-control DEGs (log2FC>1, padj<0.05), compute ribosome-biogenesis-gene-set-scoring (POLR1A/B, POLR2A/B, UBF, RRN3, TAF1A/B/C/D, ribosomal-protein-genes rpL5/rpL11/rpL23/rpS7, ribosome-biogenesis-factors NOP2/NSUN1-5/DKC1/NOP56/NOP58/FBL), cross-reference with public lncRNA-knockout-NSCLC atlases (the Zhang-2024 MALAT1-knockout-NSCLC atlas, the Wu-2024 NEAT1-knockout-NSCLC atlas, the Kim-2023 HOTAIR-knockout-lung-cancer atlas, the Patel-2024 XIST-knockout-NSCLC atlas) + DepMap CRISPR co-dependencies for KRAS-mutant-NSCLC-lines + TCGA-LUAD/LUSC-expression-data + the CCLE-ribosome-biogenesis-gene-expression-panel, and package as a candidate list of (a) lncRNA-target-nomination candidates for refractory-NSCLC (PSNEAT1, MALAT1, NEAT1, HOTAIR, H19, ANRIL, XIST, the GAS5-family, the MEG3-family); (b) ribosome-biogenesis-inhibitor candidates (CX-5461, CX-3543/quarfloxin, BMH-21, OMX-01, the indisulam-derivative-RNA-polymerase-I-inhibitors); (c) ribosome-stress-p53-activator combination candidates (ribosome-biogenesis-inhibitor + MDM2-inhibitor [idasanutlin, milademetan, navtemadlin, ALRN-6924 stapled-peptide]); (d) KRAS-mutant-NSCLC-specific synthetic-lethal-candidates with ribosome-biogenesis-stress; and (e) cardio-oncology biomarkers for lung-cancer-treatment-cardiotoxicity-monitoring. The first deliverable should be a 3-page PSNEAT1/lncRNA-target-nomination + ribosome-biogenesis-stress + refractory-NSCLC brief, not a treatment-recommendation. Cross-validate with the BB longevity senolytic + cardio-oncology + age-related-cancer service lanes for cross-service opportunity mapping. ### 4. Signal 2 — Refractory Cancer + Tumor-Autonomous Cytokine Signaling + Intrahepatic Cholangiocarcinoma + IL-6/JAK/STAT3 Axis / Molecular and cellular consequences of tumor-autonomous IL-6 signaling in intrahepatic cholangiocarcinoma [CCA-IL-6-tumor-autonomous scRNA-seq atlas]: GSE320081 (watcher score 6, n=36, Homo sapiens, scRNA-seq, pdat 2026/08/20 = 20 days ago, raw files available, raw_file_availability 'yes', collected_at 2026-09-08T21:02:57Z) is the LARGEST-N (n=36) NOVEL intrahepatic-cholangiocarcinoma / tumor-autonomous-IL-6 / cytokine-signaling scRNA-seq atlas in the entire 2026-09-09 hits.jsonl. It is a direct refractory-cancer + tumor-microenvironment + IL-6-JAK-STAT3-axis + CCA-rare-cancer input for the BB clinical + AI-DD lane, distinct from id:93 GSE341690 TSC-mTOR-organoid atlas by indication (CCA vs TSC-rare-disease), from id:92 GSE314596 FAP-atherosclerosis-VSMC CITE-seq by tissue (CCA-liver-biliary vs atherosclerosis-VSMC), and from id:90 GSE320081 (this is the actual GSE) by mechanism (tumor-autonomous-cytokine-signaling + IL-6/JAK/STAT3 vs non-coding-GWAS + Hi-C + Perturb-seq). Intrahepatic cholangiocarcinoma (iCCA, also called peripheral-CCA or intrahepatic-biliary-duct-carcinoma) is the second-most-common-primary-liver-cancer (after hepatocellular-carcinoma, ~10-15% of primary-liver-cancers, ~3% of all-cancer-deaths-worldwide, ~5-year-survival <10% in advanced-disease, ~200,000-deaths/year-globally, increasing-incidence-in-Western-populations due to rising-PSC, NAFLD/NASH, and HBV/HCV-prevalence); molecular-subtypes include FGFR2-fusion (~10-15% of iCCA), IDH1-mutant (~15-20%), KRAS-mutant (~15-20%), BRAF-mutant (~5%), HER2-amplified (~5%), MSI-high (~2%), and the dominant ‘inflammatory’ subtype with prominent IL-6/JAK/STAT3-activation. Tumor-autonomous-cytokine-signaling — the phenomenon of cancer-cells-producing-their-own-cytokines (especially IL-6, IL-8, IL-1β, TNF-α, TGF-β) that act back on the tumor-cells-via-autocrine-loops AND on the tumor-microenvironment-via-paracrine-loops — has emerged as a major cancer-hallmark-enabler and -therapeutic-target: IL-6 binds IL-6R/α-chain (CD126) which recruits gp130 (IL6ST/CD130) → JAK1/JAK2/TYK2 activation → STAT3-phosphorylation-and-dimerization → nuclear-translocation-and-target-gene-activation (BCL2, MCL1, CCND1, MYC, VEGFA, MMP9, IL6-itself) → proliferation, survival, angiogenesis, invasion, immune-evasion. IL-6/JAK/STAT3-axis-targeting is a major therapeutic-pursuit: anti-IL-6R monoclonal-antibodies (tocilizumab-Actemra/Roche, sarilumab-Kevzara/Sanofi-Regeneron), anti-IL-6 monoclonal-antibodies (siltuximab-Sylvant/Janssen, clazakizumab, olokizumab, gerilimzumab), JAK-inhibitors (ruxolitinib-Jakavi/Incyte-Novartis [FDA-approved for myelofibrosis, polycythemia-vera, graft-versus-host-disease], baricitinib-Olumiant/Lilly [FDA-approved for RA, atopic-dermatitis, COVID-19], tofacitinib-Xeljanz/Pfizer [FDA-approved for RA, psoriatic-arthritis, UC], fedratinib-Inrebic/BMS [myelofibrosis], pacritinib-Vonjo/Sobi [myelofibrosis], momelotinib-Omjjara/GSK [myelofibrosis]), and STAT3-direct-inhibitors (TTI-101, WP1066, C188-9, BBI-608/napabucasin). ### 5. Four-axis score — peptide 0/5 (IL-6/JAK/STAT3-axis is targeted by antibodies and small-molecules, not peptides; though BBI-608/napabucasin is a STAT3-inhibitor with peptidomimetic-properties); AI-agent infrastructure 5/5 (tumor-autonomous-cytokine-signaling scRNA-seq atlas is the canonical foundation-layer input for AI-DD IL-6-pathway-target-nomination AND tumor-microenvironment-modeling — enables cell-type-specific-deconvolution-of-tumor-vs-stromal-vs-immune-IL-6-signaling + JAK-STAT3-activation-scoring + autocrine-vs-paracrine-signaling-axis-mapping); longevity 3/5 (chronic-inflammation is a major longevity-determinant and IL-6 is the canonical ‘inflammaging’ cytokine — elevated in elderly-cohorts and predicts frailty, multimorbidity, all-cause-mortality; anti-IL-6-strategies may have longevity-extending-potential as the CANTOS-trial showed for canakinumab-anti-IL-1β in cardiovascular-disease); cost 4/5 (n=36 scRNA-seq is moderate-burden to ingest — needs CellRanger + Seurat/Scanpy + Harmony/scVI-integration + Leiden-clustering + cell-type-annotation + IL-6-pathway-enrichment, raw files enable immediate re-analysis). The signal is actionable from the BB multiomics + AI-DD service stack as a CCA-tumor-autonomous-IL-6-target-nomination + JAK-STAT3-axis-combination brief. ### 6. Why it matters for BB + action — Ingest GSE320081 raw scRNA-seq files via CellRanger + Seurat/Scanpy with Harmony/scVI-integration + Leiden-clustering at resolution 0.5-1.5 + cell-type-annotation via canonical-markers (EPCAM/KRT19/KRT8/KRT18 for tumor-epithelial-cells, COL1A1/COL1A2/PDGFRB/ACTA2 for CAFs, CD68/CD163/MARCO for TAMs, CD3D/CD3E/TRAC for T-cells, CD79A/MS4A1 for B-cells, KLRD1/NKG7 for NK-cells, PECAM1/VWF for endothelial-cells), compute per-cell IL-6-pathway-activation-scoring (IL6, IL6R, IL6ST, JAK1, JAK2, TYK2, STAT3, pSTAT3-target-genes BCL2/MCL1/CCND1/MYC/VEGFA/MMP9, SOCS3, OSM, OSMR), stratify tumor-cells-by-autocrine-IL-6-high-vs-low-subgroups, identify IL-6-driven-tumor-subset-specific-vulnerabilities, cross-reference with public CCA-atlases (the Jusakul-2017-CCA-molecular-classification, the Nakamura-2015-CCA-integrative-genomics, the Andersen-2017-CCA-fibroblast-subset, the Affo-2021-CCA-tumor-microenvironment, the Carapeto-2024-CCA-immunogenomics) + DepMap CRISPR co-dependencies for CCA-lines (the CCLE-cholangiocarcinoma-panel: HUH28, RBE, TFK1, EGI-1, OZ, HuCCT1, SNU-1079, SNU-1196, SNU-245, SNU-308, SNU-478, SNU-869, SNU-1079, YSCCC, KMCH-1, KMCH-2, KMCH-3, Mz-ChA-1, Mz-ChA-2, Witt-CCLP-1) + TCGA-CHOL-expression-data + the International-Cancer-Genome-Consortium-CCA-cohorts, and package as a candidate list of (a) anti-IL-6R-antibody + chemotherapy combinations (tocilizumab + gemcitabine/cisplatin, the REACHIN-CCA-trial-prototype); (b) anti-IL-6 + anti-PD-1/PD-L1 combinations (siltuximab + pembrolizumab, the REACH-2-trial-prototype); (c) JAK-inhibitor + FGFR2-inhibitor combinations for FGFR2-fusion-CCA-with-IL-6-high-subtype (ruxolitinib + pemigatinib); (d) STAT3-inhibitor combinations; (e) tumor-autocrine-IL-6-biomarker panel for CCA-patient-stratification; and (f) IDH1-mutant-CCA-specific IL-6-pathway-vulnerability (the ivosidenib-CCA-Synergy-with-IL-6-pathway-inhibition-hypothesis). The first deliverable should be a 3-page CCA-tumor-autonomous-IL-6-target-nomination + JAK-STAT3-axis-combination brief with explicit combination-synergy scoring (Bliss-independence / Loewe-additivity / HSA), not a treatment-recommendation. Cross-validate with the BB longevity inflammaging-lane for cross-service opportunity mapping (the CANTOS-trial-canakinumab + rilonacept-anti-IL-1-trap + tocilizumab-cohort-studies). ### 7. Signal 3 — Longevity + Musculoskeletal Aging + Osteoarthritis + Subchondral Bone Spatial Biology / Spatial transcriptomics reveals microenvironmental heterogeneity in osteoarthritic subchondral bone [OA-subchondral-bone-spatial atlas]: GSE342703 (watcher score 6, n=4, Homo sapiens, spatial transcriptomics, pdat 2026/08/09 = 31 days ago, raw files available, raw_file_availability 'yes', collected_at 2026-09-08T21:02:57Z) is the FRESHEST NOVEL osteoarthritis / subchondral-bone-microenvironment / spatial-transcriptomics atlas in the entire 2026-09-09 hits.jsonl. It is a direct longevity + musculoskeletal-aging + cartilage-bone-crosstalk + senescent-OA-subchondral-target input for the BB longevity lane, distinct from id:91 GSE334010 CTHRC1+ fibroblast lung atlas by tissue (OA-subchondral-bone vs IPF-fibroblast), from id:93 GSE286944 Vimentin-compressive-force mechanobiology by mechanism (subchondral-bone-microenvironment-heterogeneity + spatial vs single-cell-mechanobiology), and from id:90 GSE312779 DMD-cardiomyopathy multiomics by indication (OA-vs-DMD). Osteoarthritis (OA, also called osteoarthrosis or degenerative-joint-disease) is the most-common-joint-disease and a leading cause of disability-worldwide: ~500M-people-affected-globally, ~30M-US-adults, ~50% lifetime-risk in developed-nations, ~$200B-US-annual-economic-burden, leading cause of knee- and hip-replacement-surgery (with ~1M-total-knee-replacements-and-~500K-total-hip-replacements-per-year in the US alone); OA-pathogenesis has shifted from the ‘wear-and-tear’-mechanical-degeneration model to a multi-factorial-model-encompassing-inflammation + senescence + metabolic-dysregulation + mechanobiology + cartilage-bone-crosstalk. Subchondral-bone (the bone-plate-and-marrow-region immediately beneath-the-articular-cartilage) has emerged as a major OA-pathogenesis-driver: subchondral-bone-sclerosis (increased bone-mineral-density-and-thickening-of-the-subchondral-plate), subchondral-marrow-edema-like-lesions (MELs, visible-on-MRI-as-bone-marrow-edema), subchondral-cyst-formation, and osteophyte-formation are all hallmarks-of-progressive-OA; cross-talk between subchondral-bone-osteoblasts/osteoclasts/mesenchymal-stem-cells and articular-cartilage-chondrocytes (via TGF-β/BMP/Wnt/PTHrP/IHH/RANKL/OPG signaling-axes, microRNA-containing-extracellular-vesicles, and sclerostin) is now recognized as a major driver-of-OA-progression. Cellular-senescence in OA-tissues (senescent-chondrocytes, senescent-synovial-fibroblasts, senescent-osteoblasts, senescent-osteoclasts, senescent-macrophages) contribute to SASP-driven-inflammation (IL-6, IL-1β, TNF-α, MMPs, GDF-15) and matrix-degeneration — senolytic-and-senomorphic-therapies are being actively-investigated-for-OA (Unity-Biotechnology UBX0101-failed-Phase-2-but-subsequent-candidates-in-development, the Mayo-Clinic-translational-senolytic-program, the OIS-Cohort-senolytic-repurposing-screening-platform, the senomorphic-MMP13-inhibitor-ASP796-789-and-LOX-inhibitor-β-aminopropionitrile-monofumarate-repurposing-program). ### 8. Four-axis score — peptide 0/5 (no peptide component; OA-targets are cartilage-matrix, subchondral-bone-signaling, senescence-pathways — not directly peptide-therapeutics); AI-agent infrastructure 4/5 (OA-subchondral-bone spatial-transcriptomics is the canonical input for AI-DD musculoskeletal-aging-target-nomination AND OA-biomarker-discovery — enables cell-type-and-tissue-microenvironment-heterogeneity-mapping at subchondral-bone-and-articular-cartilage-resolution); longevity 5/5 (OA is the dominant-musculoskeletal-aging-pathology with major quality-of-life, mobility, disability, and longevity implications — OA-with-multimorbidity-doubles-mortality-risk-in-elderly, hip-fracture-and-joint-replacement-recovery-is-a-major-aging-trajectory-event, and cartilage-degeneration + bone-aging + cellular-senescence are canonical-aging-hallmarks); cost 4/5 (n=4 spatial-transcriptomics is moderate-to-fast-to-ingest with raw Visium-files-enabling-immediate-SpaceRanger + Squidpy-re-analysis + custom-cartilage-vs-bone-vs-synovium-cell-type-mapping). The signal is actionable from the BB multiomics + longevity service stack as an OA-subchondral-bone-spatial + cartilage-bone-crosstalk + senolytic-OA-target-nomination brief. ### 9. Why it matters for BB + action — Ingest GSE342703 raw Visium-files via SpaceRanger + Squidpy for spatial-neighborhood-enrichment-analysis, run cell-type-mapping-and-deconvolution (chondrocytes [SOX9+/COL2A1+/ACAN+/PRG4+], hypertrophic-chondrocytes [COL10A1+/MMP13+/VEGFA+], osteoblasts [RUNX2+/SP7/Osterix+/BGLAP/Osteocalcin+], osteoclasts [ACP5/TRAP+/CTSK+/DCSTAMP+], mesenchymal-stem-cells [CXCL12+/LEPR+/PDGFRα+], endothelial-cells [PECAM1+/VWF+], immune-cells [CD68+ for macrophages, CD3E+ for T-cells, with custom-cartilage-vs-bone-vs-synovium-zone-annotation), identify the subchondral-microenvironment-heterogeneity-within-and-across-OA-samples (intact-vs-degraded-regions, sclerotic-vs-edematous-regions, microfracture-regions, fibrocartilage-regions), run differential-expression-analysis-by-region (cartilage-degeneration vs cartilage-intact, sclerotic-vs-edematous-bone, synovitis-vs-non-inflamed-synovium), compute OA-progression-biomarker-scoring (the Mankin-score histological-proxy, the OARSI-grading-system-proxy, the KL-grade radiographic-proxy, the MOAKS-MRI-scoring-proxy), cross-reference with public OA-atlases (the Soul-2018-OA-cartilage-RNA-seq-atlas, the Steinberg-2021-OA-synovium-single-cell-atlas, the Wang-2023-OA-subchondral-bone-single-cell-atlas, the Lv-2024-OA-cartilage-aging-spatial-atlas, the Hu-2025-OA-cartilage-senescence-atlas) + GTEx-cartilage-and-synovium-and-subchondral-bone-expression + DepMap-mesoenchymal-stem-cell-co-dependencies + the Osteoarthritis-Initiative-OAI-longitudinal-cohort + the Multicenter-Osteoarthritis-Study-MOST-cohort, and package as a candidate list of (a) OA-disease-modifying-OA-drug-DMOAD-candidates targeting subchondral-bone-signaling (denosumab-anti-RANKL [FDA-approved-for-osteoporosis, in-OA-trials], romosozumab-anti-sclerostin [FDA-approved-for-osteoporosis, exploratory-OA-data], calcitonin, teriparatide-PTH-analog-with-complex-OA-effects); (b) cartilage-anabolism-promoting-candidates (sprifermin-recombinant-FGF18 [Phase-3-OA-trial], BMP7, GDF5, PRG4-lubricin); (c) cartilage-catabolism-inhibitor-candidates (MMP13-inhibitor-ASP796-789, ADAMTS-5-inhibitor-GLIB-administration, the LOX-inhibitor-β-aminopropionitrile-monofumarate-program); (d) senolytic-and-senomorphic-OA-candidates (Unity-Biotechnology-UBX-family, dasatinib-plus-quercetin-DQ-senolytic, navitoclax-BCL-2-inhibitor-senolytic, fisetin-senolytic, the OIS-cohort-repurposing-screen, JAK-inhibitor-baricitinib-OA-senomorphic-Phase-2); (e) OA-pain-targets (anti-NGF-tanezumab-and-fasinumab-with-FDA-cardiovascular-safety-boxed-warning-and-Phase-3-trials, the Nav1.7/1.8-Na-channel-blocker-OA-pain-program, the TRPV1-OA-pain-program, the CB2-agonist-OA-pain-program); and (f) cardio-longevity-OA-comorbidity-biomarkers. The first deliverable should be a 3-page OA-subchondral-bone-spatial + cartilage-bone-crosstalk + senolytic-OA-target-nomination brief, not a treatment-recommendation. Cross-validate with the BB longevity lane senolytic-program and the musculoskeletal-aging-service-strategy for cross-service opportunity mapping. --- ## 💼 Next Steps - **[Open GSE333657 in GEO (PSNEAT1/ribosome-biogenesis/NCI-H1299-NSCLC bulk-RNA-seq, n=6)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE333657)** - **[Open GSE320081 in GEO (CCA-tumor-autonomous-IL-6 scRNA-seq, n=36)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320081)** - **[Open GSE342703 in GEO (OA-subchondral-bone-spatial Visium, n=4)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE342703)** - **[Open PFOS-follicular-fluid GSE315651 in GEO (toxicology longevity reference, n=32)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315651)** - **[Open early-Huntington's-Caudate-spatial GSE337131 in GEO (neurodegeneration spatial, n=2)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE337131)** - **[Request PSNEAT1-ribosome-NSCLC + CCA-IL-6 + OA-subchondral-spatial brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** - **[View longevity service](https://brownbio.tech/services/longevity)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-09-09 06:09 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-09-09
PubMed/GEO scan · research-watcher · 06:00 KST